Antibodies

29 Oct 2020 Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
29 Oct 2020 FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
29 Oct 2020 Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC
29 Oct 2020 CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
29 Oct 2020 Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial
28 Oct 2020 Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications
28 Oct 2020 ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
28 Oct 2020 miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
28 Oct 2020 XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer
28 Oct 2020 ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer
27 Oct 2020 BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
27 Oct 2020 CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
26 Oct 2020 HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
26 Oct 2020 CTA approval of BioInvent’s BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial
26 Oct 2020 Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
26 Oct 2020 GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
26 Oct 2020 NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors
26 Oct 2020 Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
23 Oct 2020 First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
23 Oct 2020 IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
22 Oct 2020 Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
22 Oct 2020 Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
22 Oct 2020 Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
21 Oct 2020 Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk
21 Oct 2020 Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top